Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q1

9273.TEDINET S100SAN2
Period2023-07-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥5.8bn2023-07-01 → 2023-09-30Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥5.4bn2022-07-01 → 2022-09-30Cons.Net sales
Operating income¥1.2bn2023-07-01 → 2023-09-30Cons.Operating income
Operating income¥1.0bn2022-07-01 → 2022-09-30Cons.Operating income
Ordinary income¥1.2bn2023-07-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥979m2022-07-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥1.2bn2023-07-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥979m2022-07-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥758m2023-07-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥606m2022-07-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥758m2023-07-01 → 2023-09-30Cons.Profit loss
Net income¥606m2022-07-01 → 2022-09-30Cons.Profit loss
Total assets¥28.7bnat 2023-09-30Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥26.3bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥7.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥21.2bnat 2023-09-30Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥18.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥9.6bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
EPS (basic)¥19.122023-07-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.292022-07-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio74.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥449m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥449m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥15m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2023-09-30¥4.0bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2023-09-30¥3.6bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥449m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2023-09-30¥686m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2023-09-30¥2.2bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2023-09-30¥2.2bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2023-09-30¥526m
—segment totalrevenue2023-07-01 → 2023-09-30¥6.3bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥5.8bn
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥449m
—segment totalsegment profit2023-07-01 → 2023-09-30¥1.2bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30¥6m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥4.0bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥3.5bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥501m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥672m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥337m
—segment totalrevenue2022-07-01 → 2022-09-30¥5.9bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥5.4bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥501m
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 346
ItemContextValueUnit
Shareholders equityPrior1YearInstant20899787000JPY
Shareholders equityCurrentQuarterInstant21181950000JPY
Valuation difference on available for sale securitiesPrior1YearInstant11915000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant20848000JPY
Deferred gains or losses on hedgesPrior1YearInstant11785000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant9054000JPY
Valuation and translation adjustmentsPrior1YearInstant23700000JPY
Valuation and translation adjustmentsCurrentQuarterInstant29903000JPY
Net assetsPrior1YearInstant20923488000JPY
Net assetsCurrentQuarterInstant21211853000JPY
Liabilities and net assetsPrior1YearInstant28464493000JPY
Liabilities and net assetsCurrentQuarterInstant28654702000JPY
Net salesPrior1YTDDuration5358608000JPY
Net salesCurrentYTDDuration5823138000JPY
Cost of salesPrior1YTDDuration3837240000JPY
Cost of salesCurrentYTDDuration4100088000JPY
Gross profitPrior1YTDDuration1521367000JPY
Gross profitCurrentYTDDuration1723049000JPY
Selling general and administrative expensesPrior1YTDDuration506256000JPY
Selling general and administrative expensesCurrentYTDDuration525893000JPY
Operating incomePrior1YTDDuration1015111000JPY
Operating incomeCurrentYTDDuration1197156000JPY
Interest and dividends income noiPrior1YTDDuration859000JPY
Interest and dividends income noiCurrentYTDDuration907000JPY
Commission fee noiPrior1YTDDuration3088000JPY
Commission fee noiCurrentYTDDuration672000JPY
Compensation income noiPrior1YTDDuration4922000JPY
Compensation income noiCurrentYTDDuration413000JPY
Other noiPrior1YTDDuration879000JPY
Other noiCurrentYTDDuration1552000JPY
Non operating incomePrior1YTDDuration9749000JPY
Non operating incomeCurrentYTDDuration3546000JPY
Interest expenses noePrior1YTDDuration2036000JPY
Interest expenses noeCurrentYTDDuration1670000JPY
Foreign exchange losses noePrior1YTDDuration42725000JPY
Foreign exchange losses noeCurrentYTDDuration7995000JPY
Other noePrior1YTDDuration784000JPY
Other noeCurrentYTDDuration0JPY
Non operating expensesPrior1YTDDuration45545000JPY
Non operating expensesCurrentYTDDuration9666000JPY
Ordinary incomePrior1YTDDuration979315000JPY
Ordinary incomeCurrentYTDDuration1191036000JPY
Income before income taxesPrior1YTDDuration979315000JPY
Income before income taxesCurrentYTDDuration1191036000JPY
Income taxes currentPrior1YTDDuration352795000JPY
Income taxes currentCurrentYTDDuration417837000JPY
Income taxes deferredPrior1YTDDuration20619000JPY
Income taxes deferredCurrentYTDDuration15613000JPY
Income taxesPrior1YTDDuration373415000JPY
Income taxesCurrentYTDDuration433450000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2023-09-30pass